LYEL P&L Curve
Lyell Immunopharma, Inc. (LYEL) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $351.6M, listed on NASDAQ, employing roughly 161 people, carrying a beta of -0.07 to the broader market. Lyell Immunopharma, Inc. Led by Lynn Seely, public since 2021-06-17.
A profit/loss curve charts the theoretical gain or loss of an options position across a range of underlying prices. It helps traders visualize risk, identify breakeven points, and compare strategies before committing capital.
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $351.6M
- Employees
- 161
- IPO Date
- 2021-06-17
- CEO
- Lynn Seely
- Beta
- -0.07
As of Nov 13, 2026, the Lyell Immunopharma, Inc. spot price is $14.46; P&L scenarios can be constructed from the options chain. Payoff diagrams should be rebuilt from the live options chain; the preceding values are illustrative and assume a single at-the-money straddle for reference.